Next-generation therapeutics for pain and psychiatric disorders.
Patients face significant unmet
needs in neurological care
needs in neurological care
Most therapies act broadly across the central nervous system, missing the specific circuits where disease lives.
Cell Cybernetics takes a different approach by selectively targeting the neural circuits that drive disease.
Precision starts with γ1 biology
We are selectively restoring healthy inhibitory control in the
CNS by targeting γ1 subunit of GABA-A receptors
CNS by targeting γ1 subunit of GABA-A receptors
Current
GABA-A drugs
Benzodiazepines and Z-drugs target widely expressed γ2-containing GABA-A receptors, affecting healthy circuits alongside those involved in disease.
- γ2 subunit of GABA-A receptors
Two clinical programs from one platform
A single biology enables multiple independent paths to value creation
Disease area
Anxiety, Fear, PTSD
Lead indication
PTSD
Target
α1β2γ1
Lead Compound
CC2-8
Combining AI-powered discovery with wet-lab development
We combine computational and experimental biology to accelerate the discovery of differentiated drug candidates against novel therapeutic targets.
Our team
Bringing together scientific excellence,
intellectual property expertise, and pharmaceutical leadership.
intellectual property expertise, and pharmaceutical leadership.
Vladislav Sandler, PhD
CO-FOUNDER & CEO
Vladislav Sandler, PhD
CO-founder & CEO
Discovery science
Neuroscientist and stem-cell biologist; decades of published research on neural networks, calcium signaling, direct reprogramming of somatic cells and hematopoietic stem-cell biology. Co-founder & CEO, Hemogenyx Pharmaceuticals plc. Inaugural Cornell Daedalus Fund Award for Innovation. Earlier appointments at the Salk Institute, Harvard, Boston Children's Hospital, Albert Einstein College of Medicine, and Advanced Cell Technologies. PhD, UBC.
David E. Clapham, MD, PhD
CO-founder
David E. Clapham, MD, PhD
CO-founder
Ion-channel pedigree
Made key advances in ion-channel regulation by signal transduction, identifying novel channels and their interacting proteins, and defining their functions across organelles and plasma membranes.
Appointments include:
Aldo R. Castañeda Professor at Harvard Medical School, HHMI Investigator, HHMI Chief Scientific Officer, and Janelia Senior Group Leader.
Appointments include:
Aldo R. Castañeda Professor at Harvard Medical School, HHMI Investigator, HHMI Chief Scientific Officer, and Janelia Senior Group Leader.
Alexis M. Sandler, JD
CO-FOUNDER & COO
Alexis M. Sandler, JD
CO-founder & COO
IP, operations, governance
Intellectual property attorney; 20+ years representing a broad range of businesses and exempt organizations.
Co-founder, COO & Board Member, Hemogenyx Pharmaceuticals plc. Former Director of Business & Legal Affairs at Fox Entertainment Group; former General Counsel at Pace University. Now General Counsel at
a major NYC cultural institution.
AB Harvard, JD UCLA Law, MA NYU; admitted to NY and CA bars.
Co-founder, COO & Board Member, Hemogenyx Pharmaceuticals plc. Former Director of Business & Legal Affairs at Fox Entertainment Group; former General Counsel at Pace University. Now General Counsel at
a major NYC cultural institution.
AB Harvard, JD UCLA Law, MA NYU; admitted to NY and CA bars.
